→ PTOAF

Attorney Docket No.: DEX-0196

Inventors:

Serial No.:

Filing Date:

Page 2

Salceda et al.

09/807,201

April 25, 2001

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claim 1 (previously amended): A method for diagnosing the presence of prostate cancer in a patient comprising:

- (a) determining the level of SEQ ID NO: 7 or 8 in prostate cells, tissues or in blood, plasma, serum or urine from a patient; and
- (b) comparing the determined level of SEQ ID NO: 7 or 8 with the level of SEQ ID NO: 7 or 8 in prostate cells, tissues or blood, plasma, serum or urine from a normal human control, wherein an increase in the determined level of SEQ ID NO: 7 or 8 in said patient versus normal human control is associated with the presence of prostate cancer.

Claims 2-12 (canceled).

Claim 13 (new): The method of claim I wherein the level of SEQ ID NO: 7 is determined.

Claim 14 (new): The method of claim 1 wherein the level of SEQ ID NO: 8 is determined.

Attorney Docket No.:

DEX-0196

Inventors:

Salceda et al.

Serial No.: Filing Date:

09/807,201

Page 3

April 25, 2001

Claim 15 (new): The method of claim 1 wherein the level of SEQ ID NO: 7 or 8 is determined in prostate cells.

Claim 16 (new): The method of claim 1 wherein the level of SEQ ID NO: 7 or 8 is determined in prostate tissue.

Claim 17 (new): The method of claim 1 wherein the level of SEQ ID NO: 7 or 8 is determined in blood.

Claim 18 (new): The method of claim 1 wherein the level of SEQ ID NO: 7 or 8 is determined in plasma.

Claim 19 (new): The method of claim 1 wherein the level of SEQ ID NO: 7 or 8 is determined in serum.

Claim 20 (new): The method of claim 1 wherein the level of SEQ ID NO: 7 or 8 is determined in urine.